Early detection of hepatocellular carcinoma by Hyperpolarized [1- 13C]pyruvate MRI

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512490-27-00

Enrollment

Registered

2024-07-25

Start date

2023-06-19

Completion date

Unknown

Last updated

2024-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Brief summary

The raw data will be processed using both model-free and kinetic modeling approaches, which are the standards of analyzing hyperpolarized pyruvate MRI data, to quantify metabolism and perfusion.

Interventions

DRUGHyperpolarized [1-13C]pyruvate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The raw data will be processed using both model-free and kinetic modeling approaches, which are the standards of analyzing hyperpolarized pyruvate MRI data, to quantify metabolism and perfusion.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026